{"transactions":[{"id":2220841,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":125821,"kind":"person","name":"Benton Andrew","position":1,"cik":"0001867975","reported_name":"Benton Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-06-27T21:38:33.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 23, 2022, Mr. Benton was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 23, 2022, Mr. Benton was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 23, 2022, Mr. Benton was granted an option (the \"Stock Option\") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year."}],"balance_after":100850,"derivative":{"exercise_price":0.425,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001493152-22-017872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315222017872/ownership.xml","form_type":"4"}},{"id":2411300,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":125821,"kind":"person","name":"Benton Andrew","position":1,"cik":"0001867975","reported_name":"Benton Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-02-04T20:26:15.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 4, 2022, Mr. Benton was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 4, 2022, Mr. Benton was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 4, 2022, Mr. Benton was granted an option (the \"Stock Option\") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the \"Company\"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022."}],"balance_after":20000,"derivative":{"exercise_price":3.13,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001493152-22-003220","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315222003220/ownership.xml","form_type":"4"}},{"id":2643508,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":125821,"kind":"person","name":"Benton Andrew","position":1,"cik":"0001867975","reported_name":"Benton Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-07-02T22:10:25.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":65850,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"The option vests over three years with 1/3 of the total number of shares subject to the option vesting on the first anniversary of the date of grant and 1/36th of the total number of shares subject to the option vesting monthly thereafter, until fully vested on 01/24/2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the \"Merger Agreement\") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the \"Issuer\"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer (\"Merger Sub\"), and Ensysce Biosciences, Inc., a Delaware corporation (\"Ensysce\"), Merger Sub merged with and into Ensysce (the \"Merger\"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a \"Derivative Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement."}],"balance_after":65850,"derivative":{"exercise_price":3.35,"expiration_date":"2030-01-23","underlying":"Common Stock","underlying_shares":65850},"source":{"system":"sec-edgar","filing":"0001192482-21-000616","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716947/000119248221000616/edgar.xml","form_type":"4"}}]}